STI571

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypereosinophilic Syndrome

Conditions

Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL), Myeloproliferative Disorders

Trial Timeline

Mar 1, 2003 → —

NCT ID

NCT00276926

About STI571

STI571 is a phase 2 stage product being developed by Novartis for Hypereosinophilic Syndrome. The current trial status is unknown. This product is registered under clinical trial identifier NCT00276926. Target conditions include Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL), Myeloproliferative Disorders.

What happened to similar drugs?

0 of 1 similar drugs in Hypereosinophilic Syndrome were approved

Approved (0) Terminated (0) Active (1)

🔄Benralizumab + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00613171	Phase 2	Completed	Jan 2, 2008	Jan 13, 2010	Systemic Sclerosis, Scleroderma
NCT00276926	Phase 2	UNKNOWN	Mar 1, 2003	—	Hypereosinophilic Syndrome
NCT00511303	Phase 2	Completed	Aug 1, 2000	—	Chronic Myeloid Leukemia
NCT00171223	Phase 2	Completed	Dec 6, 1999	Nov 29, 2013	Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Competing Products

4 competing products in Hypereosinophilic Syndrome

See all competitors

Product	Company	Stage	Hype Score
Benralizumab + Placebo	AstraZeneca	Phase 3	44
Nilotinib	Novartis	Pre-clinical	26
imatinib mesylate	Novartis	Phase 2	27
imatinib mesylate	Novartis	Phase 2	35